Sexually Transmitted Diseases

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

1100%

+ 13 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

ViiV HealthcareNC - Durham

1 program

NgG low dose investigational vaccinePhase 1/2Vaccine1 trial

Active Trials

NCT05630859Completed1,009Est. May 2025

Human BioSciencesWV - Martinsburg

4 programs

Health-E You appN/A1 trial

P3N/A1 trial

Patient preferencesN/A1 trial

Risk Avoidance InterventionN/A1 trial

Active Trials

NCT06525064Recruiting2,752Est. Dec 2027

NCT03320512Completed246Est. Sep 2021

NCT01862133Completed136Est. Mar 2014

+1 more trials

Gilead SciencesFOSTER CITY, CA

2 programs

Pre Exposure ProphylaxisN/A

Angeles TherapeuticsCA - Los Angeles

2 programs

Risk ReductionN/A1 trial

uTECH + YMHPN/A1 trial

Active Trials

NCT01829282Unknown400Est. Jun 2017

NCT04710901Completed388Est. May 2024

Essential PharmaceuticalsNC - Raleigh

2 programs

Synthetic Nitrile CondomN/A1 trial

Synthetic Nitrile CondomsN/A1 trial

Active Trials

NCT06079060Completed305Est. Oct 2024

NCT05912283Completed600Est. Jan 2024

Kite PharmaCA - El Segundo

1 program

Pre Exposure ProphylaxisN/A1 trial

Active Trials

NCT02852226Completed30Est. Aug 2017

City TherapeuticsMA - Cambridge

1 program

SexHealthN/A1 trial

Active Trials

NCT03341975CompletedEst. May 2020

Evofem BiosciencesCA - San Diego

1 program

EVO100PHASE_31 trial

Active Trials

NCT04553068Completed1,892Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Evofem BiosciencesEVO100

ViiV HealthcareNgG low dose investigational vaccine

Human BioSciencesHealth-E You app

Essential PharmaceuticalsSynthetic Nitrile Condom

Essential PharmaceuticalsSynthetic Nitrile Condoms

Angeles TherapeuticsuTECH + YMHP

Human BioSciencesP3

City TherapeuticsSexHealth

Kite PharmaPre Exposure Prophylaxis

Human BioSciencesPatient preferences

Angeles TherapeuticsRisk Reduction

Human BioSciencesRisk Avoidance Intervention

Clinical Trials (12)

Total enrollment: 9,500 patients across 12 trials

NCT04553068 Evofem BiosciencesEVO100

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

Start: Oct 2020Est. completion: Jul 20221,892 patients

Phase 3Completed

NCT05630859 ViiV HealthcareNgG low dose investigational vaccine

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age

Start: Nov 2022Est. completion: May 20251,009 patients

Phase 1/2Completed

NCT06525064 Human BioSciencesHealth-E You app

Health-E You Efficacy Trial for Male Adolescents

Start: Jun 2026Est. completion: Dec 20272,752 patients

N/ARecruiting

NCT06079060 Essential PharmaceuticalsSynthetic Nitrile Condom

Evaluation of Synthetic Nitrile Male Condom Compared to Standard Latex Male Condom

Start: Oct 2023Est. completion: Oct 2024305 patients

N/ACompleted

NCT05912283 Essential PharmaceuticalsSynthetic Nitrile Condoms

Evaluation of 2 Synthetic Nitrile Male Condoms Compared to a Standard Latex Male Condom

Start: Jun 2023Est. completion: Jan 2024600 patients

N/ACompleted

NCT04710901 Angeles TherapeuticsuTECH + YMHP

UTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM

Start: Nov 2020Est. completion: May 2024388 patients

N/ACompleted

NCT03320512 Human BioSciencesP3

P3 (Prepared, Protected, emPowered)

Start: May 2019Est. completion: Sep 2021246 patients

N/ACompleted

NCT03341975 City TherapeuticsSexHealth

Enhanced SexHealth Intervention to Improve Adolescent Outcomes

Start: Dec 2017Est. completion: May 2020

N/ACompleted

NCT02852226 Kite PharmaPre Exposure Prophylaxis

CRUSH-PrEP for Women Project

Start: May 2016Est. completion: Aug 201730 patients

N/ACompleted

NCT01862133 Human BioSciencesPatient preferences

Aspiring to Awesome- Patient Preference Privacy Selections in EMR

Start: Aug 2013Est. completion: Mar 2014136 patients

N/ACompleted

NCT01829282 Angeles TherapeuticsRisk Reduction

Eban II: Intervention for HIV Sero-Discordant Couples

Start: Jul 2012Est. completion: Jun 2017400 patients

N/AUnknown

NCT00167505 Human BioSciencesRisk Avoidance Intervention

All About Youth: Evaluation of Sexual Risk Avoidance and Risk Reduction Programs for Middle School Students

Start: Sep 2006Est. completion: Jul 20101,742 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 9,500 patients

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.